Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Clinical testing should be individualized, not based on populations
David R. Walt
David R. Walt
View: Text | PDF
Viewpoint

Clinical testing should be individualized, not based on populations

  • Text
  • PDF
Abstract

Authors

David R. Walt

×

Figure 1

Hypothetical data set depicting biomarkers with a narrow or wide distribution range across patient populations.

Options: View larger image (or click on image) Download as PowerPoint
Hypothetical data set depicting biomarkers with a narrow or wide distrib...
Left: The baseline levels of a biomarker vary over time in multiple individuals (each line represents a unique individual). The range of healthy baseline levels is narrow, as indicated by the shaded area (peach). One individual’s biomarker concentration increases over time (red) and eventually goes outside the normal range, making it easy to detect an abnormal value. Right: The range of healthy baseline levels varies widely between patients. One individual’s biomarker concentration increases significantly over time (red) but stays within the normal distribution range. For this individual, it is important to compare the biomarker concentration value to previous measurements to ascertain that the level exceeds this individual’s baseline. Illustrated by Rachel Davidowitz.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts